Absorption and distribution. Upadacitinib is an orally administered small-molecule JAK inhibitor whose systemic exposure is shaped primarily by CYP3A4-mediated metabolism. Co-administration with the strong CYP3A4 inhibitor ketoconazole produced a 70% and 75% increase in C max and AUC ∞, respectively, while the strong inducer rifampicin caused a 50% decrease in C max and 60% decrease in AUC ∞, underscoring that any strong CYP3A modulator can shift exposure substantially. Across the evaluated dose range, plasma exposure is approximately dose proportional with no significant accumulation with repeated BID dosing of the IR formulation. The concentration–time profile follows bi-exponential disposition, with a terminal elimination half-life of 6 to 16 hours and a shorter functional half-life of 3 to 4 hours. Food slows absorption but does not substantially affect total exposure: a high-fat meal reduced C max by 23% without changing AUC ∞. Upadacitinib is 52% bound to plasma proteins, limiting clinically meaningful displacement interactions, and approximately 20% of the administered dose is eliminated in urine as unchanged drug. Mild and moderate renal impairment are associated with 16% and 32% higher AUC, respectively, relative to normal renal function.

ATP-competitive JAK1 engagement. Once absorbed, upadacitinib reaches immune-relevant compartments and engages JAK family kinases at their conserved ATP-binding site. JAK inhibitors function as competitive inhibitors of ATP that prevent its binding to the tyrosine kinase domain of JAKs, and upadacitinib was designed to exploit structural differences in this pocket to achieve preferential JAK1 inhibition. In biochemical assays, the drug yielded an IC 50 of 0.045 μM for JAK1 versus 0.109 μM for JAK2, with >40-fold selectivity over JAK3 and approximately ~100-fold selectivity over TYK2. Structure-based docking rationalises these differences: in the active site, upadacitinib forms three hydrogen bonds with JAK1 (E883, E957, L959) compared with two for JAK2 and JAK3 and one for TYK2. An additional hydrogen bond on the JAK1 glycine loop further stabilises binding, and the hinge-region network is also more extensive, with four hinge hydrogen bonds identified for JAK1 versus two each for JAK2 and JAK3.

Interruption of JAK–STAT signalling. Occupation of the JAK1 ATP site prevents the autophosphorylation and transphosphorylation events required for STAT activation. Pharmacodynamic studies in humans demonstrate pathway-selective inhibition: JAK1-mediated IL-6–induced pSTAT3 was inhibited ~50% at the 3 mg dose of upadacitinib, whereas 12 mg was necessary to inhibit IL-7–driven pSTAT5 to a comparable degree. This four-fold dose separation reflects the differential dependence of these cytokine axes on JAK1: IL-6 signals exclusively through JAK1/JAK2 heterodimers, whereas IL-7 uses a JAK1/JAK3 pairing at the common γ-chain, making pSTAT5 inhibition less sensitive to preferential JAK1 blockade at lower exposures.

STAT-driven transcriptional reprogramming. Phosphorylated STAT proteins dimerize and translocate to the nucleus, where they bind to DNA and regulate gene transcription. In ex vivo whole-blood assays, upadacitinib showed cell-type–dependent potency, blocking IL-6– and IFNγ–driven STAT3 phosphorylation in the low nanomolar range and EPO-driven STAT5 only at ~60-fold higher concentrations. At the proteome level, differential protein changes under upadacitinib treatment in RA clustered into four clusters enriched for proteins related to IL-6, IFN, leukocyte trafficking, and macrophage activation. Pathway inference from these biomarker data indicates that upadacitinib exerts broad inhibitory activity directly on multiple JAK1-dependent pathways (IFNα/β, IFNγ, IL-6, IL-2, IL-5, IL-7, OSM) and indirectly on JAK1-independent upstream pathways (IL-1, IL-23, IL-17, TNFα), converging on functional suppression of leukocyte activation, inflammatory response, and connective tissue damage programmes.

Parallel pathway selectivity and its limits. The selectivity rationale for preferential JAK1 inhibition centres on sparing JAK2-dependent biology, particularly erythropoiesis. Consistent with this design goal, inhibition of JAK1-dependent cytokine signalling was reported as ~60-fold more potent than activity on erythropoietin signalling, which depends exclusively on JAK2. This selectivity is not absolute, however: upadacitinib did not attenuate LPS-induced IL-23 or TNFα from entheseal myeloid cells, indicating that not all inflammatory outputs are uniformly suppressed across tissue contexts.

Clinical translation. Exposure–response modelling aligned these mechanistic properties to dose selection: extended-release regimens of 15 mg and 30 mg once daily were predicted to provide the optimal balance of benefit and risk in moderately to severely active RA, informing Phase III dose selection. In ulcerative colitis induction studies, clinical remission rates were higher with upadacitinib 45 mg daily versus placebo (26% vs 5% in U-ACHIEVE; 33% vs 4% in U-ACCOMPLISH). Preclinically, oral upadacitinib administered at first signs of disease produced dose- and exposure-dependent reductions in paw swelling in adjuvant-induced arthritis, linking systemic exposure, JAK1 pathway inhibition, and anti-inflammatory phenotypes in a disease-relevant model.